SEL212

Unassigned

New Medicines

Chronic severe refractory and tophaceous gout

Information

New molecular entity
SOBI (Swedish Orphan Biovitrum)
SOBI (Swedish Orphan Biovitrum)

Development and Regulatory status

None
None
Phase III Clinical Trials

Category

SEL 212 comprises a potent uric acid lowering uricase enzyme - pegsiticase (SEL-037)co-administered with SVP-Rapamycin for prevention of anti-drug antibodies. It lowers uric acid burden, improving pain, inflammation of joints and debilitating flares. [2,3]
Gout affects about 1 in 100 adults and men are more commonly affected than women. A first attack of gout typically develops in middle age but it sometimes occurs in younger people. There is a family history of gout in about 1 in 5 cases.[1]
Chronic severe refractory and tophaceous gout
Intravenous